Ablation Equipments - Medical Devices Pipeline Assessment, 2017

GlobalData
145 Pages - GLDATA62961
$2,500.00


The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Ablation Equipments pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
•Extensive coverage of the Ablation Equipments under development
•The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
•The report reviews the major players involved in the development of Ablation Equipments and list all their pipeline projects
•The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
•The report provides key clinical trial data of ongoing trials specific to pipeline products
•Recent developments in the segment / industry
Reasons to buy

The report enables you to - •Formulate significant competitor information, analysis, and insights to improve R&D strategies
•Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
•Identify and understand important and diverse types of Ablation Equipments under development
•Develop market-entry and market expansion strategies
•Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
•In-depth analysis of the product’s current stage of development, territory and estimated launch date


Search inside this report









Download Sample



Online Download
$2,500
 Add to Cart


Site License
$5,000
 Add to Cart


Global Site License
$7,500
 Add to Cart








Research assistance



US: 800.298.5699

Int'l: +1.240.747.3093



Live help





Download our eBook: How to Succeed Using Market Research

Learn

'

• Introduction
o Ablation Equipments Overview
• Products under Development
o Ablation Equipments - Pipeline Products by Stage of Development
 Table figure 1: Ablation Equipments - Pipeline Products by Stage of under Development
 Table Ablation Equipments - Pipeline Products by Stage of under Development
o Ablation Equipments - Pipeline Products by Territory
 Table figure 2: Ablation Equipments - Pipeline Products by Territory
 Table Ablation Equipments - Pipeline Products by Territory
o Ablation Equipments - Pipeline Products by Regulatory Path
 Table figure 3: Ablation Equipments - Pipeline Products by Regulatory Path
 Table Ablation Equipments - Pipeline Products by Regulatory Path
o Ablation Equipments - Pipeline Products by Estimated Approval Date
 Table figure 4: Ablation Equipments - Pipeline Products by Estimated Approval Date
 Table Ablation Equipments - Pipeline Products by Estimated Approval Date
o Ablation Equipments - Ongoing Clinical Trials
 Table figure 5: Ablation Equipments - Ongoing Clinical Trials
 Table Ablation Equipments - Ongoing Clinical Trials
• Ablation Equipments - Pipeline Products under Development by Companies
o Ablation Equipments Companies - Pipeline Products by Stage of Development
 Table Ablation Equipments Companies - Pipeline Products by Stage of Development
o Ablation Equipments - Pipeline Products by Stage of Development
 Table Ablation Equipments - Pipeline Products by Stage of Development
• Ablation Equipments Companies and Product Overview
o AngioDynamics Inc Company Overview
 AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table AngioDynamics Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Status
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Product Description
 Table NanoKnife System - Pancreatic Cancer - Product Status
 Table NanoKnife System - Pancreatic Cancer - Product Description
 Table NanoKnife System - Prostate Cancer - Product Status
 Table NanoKnife System - Prostate Cancer - Product Description
 Table Next Generation NanoKnife System - Product Status
 Table Next Generation NanoKnife System - Product Description
 Table AngioDynamics Inc - Ongoing Clinical Trials Overview
 Table NanoKnife System - Prostate Cancer - Irreversible Electroporation(IRE) for Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial
 Table NanoKnife System - Prostate Cancer - Multi-center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer
 Table NanoKnife System - Pancreatic Cancer - A Clinical Research about Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer
 Table NanoKnife System - Pancreatic Cancer - A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas
 Table NanoKnife System - Pancreatic Cancer - Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study
 Table NanoKnife System - Pancreatic Cancer - Pilot-study: Non-thermal Ablation Using Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma - A Phase I Clinical Trial – PANFIRE
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - A Phase II Clinical Trial (COLDFIRE-2 Study)
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma – Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma - Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)
 Table NanoKnife Low Energy Direct Current System - Hepatocellular Carcinoma – Irreversible Electroporation (IRE) for Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
 Table Next Generation NanoKnife System - The Safety and Feasibility of Irreversible Electroporation for the Ablation of Small Renal Masses
o CPSI Biotech Company Overview
 CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview
 Table CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview
 Table Pressurized Sub-Cooled Nitrogen System - Product Status
 Table Pressurized Sub-Cooled Nitrogen System - Product Description
 Table Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Status
 Table Super-Critical Nitrogen (SCN) Cryoablation Platform - Product Description
o Creo Medical Ltd. Company Overview
 Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview
 Table Creo Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview
 Table Flexible Ablation System - Product Status
 Table Flexible Ablation System - Product Description
 Table Lung Ablation Device - Product Status
 Table Lung Ablation Device - Product Description
o Harmonic Medical Inc Company Overview
 Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Harmonic Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Status
 Table Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - Product Description
 Table Harmonic Medical Inc - Ongoing Clinical Trials Overview
 Table Symphony MRI guided High Intensity Focused Ultrasound - Leiomyomas - MRI-guided High Intensity Focused Ultrasound Ablation of Leiomyomas. Single Arm, Feasibility Study Using the Symphony - MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas.
o HistoSonics Inc Company Overview
 HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table HistoSonics Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Vortx RX - Product Status
 Table Vortx RX - Product Description
 Table HistoSonics Inc - Ongoing Clinical Trials Overview
 Table Vortx RX - Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)
o Hospital for Special Surgery Company Overview
 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview
 Table Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview
 Table Radiofrequency Ablation Device - Product Status
 Table Radiofrequency Ablation Device - Product Description
o Imricor Medical Systems Inc Company Overview
 Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Imricor Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Vision MR Ablation Catheter - Product Status
 Table Vision MR Ablation Catheter - Product Description
 Table Imricor Medical Systems Inc - Ongoing Clinical Trials Overview
 Table Vision MR Ablation Catheter - Cardiovascular Magnetic Resonance-guided Radiofrequency- Ablation for Atrial Flutter
 Table Vision MR Ablation Catheter - Evaluation of MR-enabled Systems in the Treatment of Atrial Flutter: A Prospective Pilot Study
o Innoblative Designs, Inc. Company Overview
 Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview
 Table Innoblative Designs, Inc. Pipeline Products & Ongoing Clinical Trials Overview
 Table RFA Applicator - Product Status
 Table RFA Applicator - Product Description
o Integra LifeSciences Holdings Corp Company Overview
 Integra LifeSciences Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview
 Table Integra LifeSciences Holdings Corp Pipeline Products & Ongoing Clinical Trials Overview
 Table CUSA Ultrasonic Tissue Ablation System - Liver - Product Status
 Table CUSA Ultrasonic Tissue Ablation System - Liver - Product Description
o Intratherm, Llc Company Overview
 Intratherm, Llc Pipeline Products & Ongoing Clinical Trials Overview
 Table Intratherm, Llc Pipeline Products & Ongoing Clinical Trials Overview
 Table CITT Device - Product Status
 Table CITT Device - Product Description
o Medtronic plc Company Overview
 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
 Table Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
 Table Barrx 360 Express RFA Balloon Catheter - Product Status
 Table Barrx 360 Express RFA Balloon Catheter - Product Description
 Table Nerve Cryoablation System - Product Status
 Table Nerve Cryoablation System - Product Description
o Memorial Sloan Kettering Cancer Center Company Overview
 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
 Table Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
 Table Image-Guided Ablation Device - Product Status
 Table Image-Guided Ablation Device - Product Description
o Mirabilis Medical Inc Company Overview
 Mirabilis Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Mirabilis Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Mirabilis System - Product Status
 Table Mirabilis System - Product Description
 Table Mirabilis Medical Inc - Ongoing Clinical Trials Overview
 Table Mirabilis System - Directed Ablation of Uterine Fibroids Using a Noninvasive Approach: DIANA
o Prosurg Inc Company Overview
 Prosurg Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Prosurg Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table ImaGel - Product Status
 Table ImaGel - Product Description
o Pulse Biosciences, Inc. Company Overview
 Pulse Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
 Table Pulse Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
 Table PulseTx System - Seborrheic Keratosis - Product Status
 Table PulseTx System - Seborrheic Keratosis - Product Description
 Table PulseTx System - Soft Tissue Ablation - Product Status
 Table PulseTx System - Soft Tissue Ablation - Product Description
 Table Pulse Biosciences, Inc. - Ongoing Clinical Trials Overview
 Table PulseTx System - Soft Tissue Ablation - First-of-its-kind PulseTx System in Pilot Study in Dermatology
 Table PulseTx System - Seborrheic Keratosis - Clinical Evaluation of Safety and Efficacy of Nano-pulse Stimulation Technology for Seborrheic Keratosis Lesions
o Southern Illinois University Carbondale Company Overview
 Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview
 Table Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview
 Table Thermoablation Probe - Product Status
 Table Thermoablation Probe - Product Description
o Thermedical Inc Company Overview
 Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table Thermedical Inc Pipeline Products & Ongoing Clinical Trials Overview
 Table SERF Ablation System - Fibroids - Product Status
 Table SERF Ablation System - Fibroids - Product Description
o TransEnterix, Inc. Company Overview
 TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview
 Table TransEnterix, Inc. Pipeline Products & Ongoing Clinical Trials Overview
 Table Barrett's Excision Device - Product Status
 Table Barrett's Excision Device - Product Description
o University of California San Francisco Company Overview
 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
 Table University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
 Table Robotic Needle Ablation Tool And Securement Device - Product Status
 Table Robotic Needle Ablation Tool And Securement Device - Product Description
o University of Texas at Austin Company Overview
 University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview
 Table University of Texas at Austin Pipeline Products & Ongoing Clinical Trials Overview
 Table Plasmonic Laser Ablation Device - Product Status
 Table Plasmonic Laser Ablation Device - Product Description
o University of Wisconsin-Stout Company Overview
 University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview
 Table University of Wisconsin-Stout Pipeline Products & Ongoing Clinical Trials Overview
 Table Microwave Ablation Probe - Product Status
 Table Microwave Ablation Probe - Product Description
• Ablation Equipments- Recent Developments
o Dec 12, 2017: Stryker announces Mr. Howard E. Cox, Jr. will retire from Board of Directors
o Nov 21, 2017: Medtronic Reports Second Quarter Financial Results
o Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue
o Nov 07, 2017: Misonix Reports First Quarter Fiscal Year 2018 Financial Results
o Nov 06, 2017: Ethicon Celebrates 130 Years of Transforming Surgery to Advance Patient Outcomes
o Nov 03, 2017: Smith & Nephew Third Quarter 2017 Trading Report
o Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report
o Nov 01, 2017: AtriCure Reports Third Quarter 2017 Financial Results
o Oct 26, 2017: Stryker reports third quarter 2017 results
o Oct 26, 2017: Integra LifeSciences Reports Third Quarter 2017 Financial Results
o Oct 25, 2017: Baylis Medical's Kris Shah appointed to AdvaMed Accel Board of Directors
o Oct 19, 2017: CLS signs supplier agreement with University of Texas Medical Branch and receives the first order
o Oct 18, 2017: Relievant Medsystems Names Ray M. Baker, M.D. as Chief Medical Officer
o Oct 09, 2017: Smith & Nephew: Notice of Chief Executive Officer's intention to retire by end of 2018
o Oct 09, 2017: Notice of Chief Executive Officer's intention to retire by end of 2018
o Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria
o Oct 02, 2017: Smith & Nephew Announces Directorate Change
o Sep 28, 2017: AngioDynamics Reports Fiscal 2018 First Quarter Results
o Sep 26, 2017: Integra LifeSciences Provides Preliminary Assessment of Minor Damage to its Manufacturing Facility in Anasco, Puerto Rico
o Sep 20, 2017: SonaCare Medical Reports that CMS Announces Increase to ASC Payment for HIFU Prostate Ablation
o Sep 19, 2017: Relievant Medsystems Names Kevin Hykes Chief Executive Officer
o Sep 19, 2017: HistoSonics Expands Leadership Team As It Accelerates Growth
o Sep 18, 2017: Smith & Nephew Announces Change in Board of Directors
o Sep 12, 2017: Smith & Nephew: Appointment of Marc Owen as Non-Executive Director
o Sep 11, 2017: Pulse Biosciences Announces Withdrawal and Planned Resubmission of 510(k) Application for the PulseTx System
o Aug 23, 2017: Misonix Appoints Joseph Dwyer as Chief Financial Officer
o Aug 23, 2017: Baylis Medical strengthens global expansion plans with senior hire
o Aug 22, 2017: Misonix Reports Fiscal Year 2017 Financial Results
o Aug 22, 2017: Medtronic Reports First Quarter Financial Results
o Aug 09, 2017: Novadaq Receives Court Approval for Arrangement With Stryker
o Aug 02, 2017: Stryker announces election of new Director, Mary K. Brainerd
o Jul 27, 2017: Smith & Nephew Second Quarter and First Half 2017 Results
o Jul 27, 2017: Stryker reports second quarter 2017 results
o Jul 27, 2017: AtriCure Reports Second Quarter 2017 Financial Results
o Jul 26, 2017: Integra LifeSciences Reports Second Quarter 2017 Financial Results
o Jul 18, 2017: AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
o Jul 18, 2017: AtriCure Announces Hiring of Chief Technology Officer
o Jul 04, 2017: Appointment of Angie Risley as Non-Executive Director and Chairman Elect of the Remuneration Committee
o Jun 29, 2017: FDA Confirms 510(K) Submission Pathway For Creo's Flexible Ablation System
o Jun 19, 2017: CSA Medical Appoints Jean Bjerke, Vice President of Marketing
o Jun 07, 2017: AngioDynamics Announces FDA Clearance for The Solero Microwave Tissue Ablation System
o Jun 07, 2017: HistoSonics Announces Addition to Management Team
o Jun 06, 2017: Pulse Biosciences Announces Treatment of First Patient in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation Technology for Seborrheic Keratosis Lesions
o May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results
o May 17, 2017: Syneron Medical Reports First Quarter 2017 Revenue of $66.9 Million
o May 12, 2017: Smith & Nephew opens state-of-the-art Research & Development Centre
o May 10, 2017: The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures
o May 05, 2017: Smith & Nephew 2017 First Quarter Trading Report
o May 04, 2017: AtriCure Reports First Quarter 2017 Financial Results
o May 04, 2017: Olympus Extends Portfolio of EndoTherapy Solutions at DDW
o May 02, 2017: Misonix Reports Third Quarter Fiscal Year 2017 Financial Results
o Apr 26, 2017: Integra LifeSciences Reports First Quarter 2017 Financial Results
o Apr 25, 2017: Stryker reports first quarter 2017 results
o Apr 20, 2017: Key Appointment to Board of Directors at Cianna Medical
o Mar 30, 2017: AngioDynamics Reports Fiscal 2017 Third Quarter Results
o Mar 23, 2017: Mirabilis Medical Announces European Approval for Non-Invasive Uterine Fibroid Treatment
o Mar 23, 2017: Mirabilis receives FDA approval for US clinical study
o Mar 14, 2017: Pulse Biosciences Submits 510(k) Application to FDA for PulseTx System
o Mar 14, 2017: AngioDynamics Receives CE Mark Certification for The Solero Microwave Tissue Ablation System
o Mar 13, 2017: Misonix Announces Second Quarters of Fiscal 2017
o Mar 13, 2017: HistoSonics Appoints Mike Blue as CEO and Board Member
o Mar 13, 2017: Misonix Files Forms 10-Q for First and Second Quarters of Fiscal 2017
o Mar 06, 2017: AtriCure Announces hiring of Senior Vice President of Clinical, Regulatory, and Scientific Affairs
o Mar 06, 2017: TransEnterix Reports Operating Results for the Fourth Quarter and Full Year 2016
o Feb 28, 2017: AtriCure Reports Fourth Quarter and Full Year 2016 Financial Results
o Feb 23, 2017: Integra LifeSciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Updates 2017 Full-Year Guidance
o Feb 21, 2017: Medtronic Reports Third Quarter Financial Results
o Feb 15, 2017: Syneron Medical Reports Fourth Quarter 2016 Revenue of $82.9 Million and Full Year 2016 Revenue $298.1 Million
o Feb 09, 2017: Smith & Nephew Fourth Quarter Trading and Full Year 2016 Results
o Feb 09, 2017: Smith & Nephew: Directorate Change
o Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors
o Jan 31, 2017: Syneron Medical Strengthens Senior Management Team with Appointment of Chief Human Resources Officer
o Jan 24, 2017: Stryker reports 2016 results and 2017 outlook
o Jan 17, 2017: Aurora Cancer Care is first in Wisconsin to perform new Nanoknife therapy technique to treat pancreatic and liver cancers
o Jan 12, 2017: Confirmation of CFO leaving Smith & Nephew
o Jan 10, 2017: Stryker provides 2016 preliminary net sales results
o Jan 09, 2017: AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2016
o Jan 06, 2017: AngioDynamics Reports Fiscal 2017 Second Quarter Results
o Dec 19, 2016: Stavros G. Vizirgianakis Appointed President and CEO of Misonix
• Appendix
o Methodology

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838